A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Taladegib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2017.
    • 29 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 26 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top